Armata Pharmaceuticals, Inc. — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Armata Pharmaceuticals received $3.7 million in non-dilutive funding from the U.S. Department of War (through MTEC/NMRC) specifically for Phase 3 clinical development of AP-SA02, a bacteriophage therapeutic for complicated Staphylococcus aureus bacteremia. This is the first Phase 3-directed tranche under a broader DoW award; cumulative DoW funding for AP-SA02 now totals $32.4 million ($28.7M previously announced plus this $3.7M increment). The Phase 3 study is anticipated to initiate in H2 2026.
Why this rating
Non-dilutive capital of $3.7M is 17.5% of company market cap; cumulative $32.4M DoW award is 153% of market cap. Extends runway and validates lead program, critical for $21.1M-market-cap biotech. Positive but not transformational—execution risk remains.
Price action (we called it positive)
before filing · preread $4.45 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.